BRIEF—Clinigen buys Japan's largest supplier of unlicensed medicines

UK-based specialty pharma company Clinigen Group has acquired International Medical Management Corporation (IMMC), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.

The acquisition adds to Clinigen’s existing footprint in the country following the launch of its Japanese business in October 2016 and is part of its strategy to become the ‘go to’ global leader in ethical access to unlicensed medicines.

IMMC, established in 2006, operates throughout Japan in sectors including niche vaccine, oncology and IVF. It currently has relationships with more than 850 hospitals and clinics.